Clementia is charting a new course to develop effective new treatments for people who have none.

Learn More

Spread the Word

About FOP

Fibrodysplasia ossificans progressiva, or FOP, is a severely disabling myopathy in which muscles, tendons and other soft tissues are progressively replaced by bone. Known as heterotopic ossification (HO), this abnormal, extra-skeletal bone eventually imprisons affected persons in a “second skeleton.” Nearly 100 percent of newborns with FOP have a hallmark toe malformation, with both big toes shortened and bent inwards resembling a bunion.

Learn More

About Palovarotene

Palovarotene is an investigational treatment with the potential to prevent the abnormal growth of bone in people with FOP, a disease for which there are currently no approved treatments. Clementia is studying palovarotene in Phase II clinical trials for people with FOP based on nonclinical studies in which palovarotene blocked abnormal bone formation in animal models of heterotopic ossification.

Learn More